Clinical trials: Localized Renal Cell Carcinoma
Pentafecta, Laparoscopic
Current Role of Pentafecta Outcomes in Open and Laparoscopic Partial Nephrectomy for Localized Renal Tumors
This study aimed to identify predictive factors associated with the achievement of pentafecta outcomes following partial nephrectomy.
- Conditions
- Pentafecta, Laparoscopic, Partial Nephrectomy, Renal Tumors
- Trial name
- NCT06969131
- Testing
- Open Partial Nephrectomy, Laparoscopic Partial Nephrectomy
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- South Valley University
Renal Carcinoma, Renal Mass
Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery
This clinical trial studies a type of ultrasound called robot-assisted laparoscopic high-intensity focused ultrasound for performing thermal ablative therapy, or sound wave therapy, in treating patients with small kidney masses…
- Trial name
- NCT02370342
- Testing
- Robot-Assisted Laparoscopic Surgery, High-Intensity Focused Ultrasound Ablation, Therapeutic Laparoscopic Surgery
- Where
- 2 sites in United States
- Sponsor
- University of Southern California
Renal Cell Carcinoma (RCC), Cancer
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing…
- Trial name
- PROTECT (NCT01235962)
- Testing
- pazopanib
- Where
- 312 sites in United States, Argentina and 24 more
- Volunteers
- 1,538 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Tumor, Renal Benign Neoplasm
Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about…
- Conditions
- Kidney Tumor, Renal Benign Neoplasm, Renal Malignant Tumor
- Trial name
- BIOPSy (NCT05728957)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Loyola University
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
The purpose of this study is to determine if Magnetic Resonance guided High Intensity Focused Ultrasound ablative therapy is safe and feasible for children, adolescents, and young adults with refractory or relapsed solid tumors.
- Conditions
- Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT02076906
- Testing
- Magnetic Resonance High Intensity Focused Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- AeRang Kim
Carcinoma, Renal Cell
Autologous Dendritic Cell Vaccine in Kidney Cancer
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
- Trial name
- NCT05127824
- Testing
- Autologous alpha-DC1/TBVA vaccine, Cabozantinib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Jodi Maranchie
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
a monocenter, open label, single arm, phase II study of the combination of axitinib with avelumab as neoadjuvant therapy in patients with intermediate to high-risk non-metastatic RCC.
- Trial name
- NCT03341845
- Testing
- Axitinib, Avelumab
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- The Netherlands Cancer Institute
Partial Nephrectomy, Hemostatic Agents
Evaluation of Hemostatic Agents in Partial Nephrectomy
This prospective randomized study aims to evaluate the effect of adjunctive hemostatic agents (FloSeal® and Surgicel®) on perioperative outcomes in patients undergoing partial nephrectomy for localized renal tumors.
- Conditions
- Partial Nephrectomy, Hemostatic Agents, Localized Renal Cell Carcinoma
- Trial name
- HEMOSTA-PN (NCT07232927)
- Testing
- Standard Parenchymal Suturing, Suturing with FloSeal®, Suturing with Surgicel®
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Ankara University
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where…
- Trial name
- NCT05863351
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- 108 sites in United States
- Volunteers
- 472 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's…
- Conditions
- Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model, Recurrent Renal Cell Cancer
- Trial name
- NCT06088134
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Mingzhao Xiao
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well vorinostat works in treating patients with locally recurrent or metastatic cancer of…
- Conditions
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00363883
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with nivolumab to the usual approach of nephrectomy followed by standard post-operative follow-up and monitoring, in treating patients…
- Conditions
- Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
- Trial name
- NCT03055013
- Testing
- Nephrectomy, Nivolumab, Patient Observation
- Where
- 413 sites in United States, Canada and 1 more
- Volunteers
- 819 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma
This trial investigates whether an online intervention, iConquerFear, can reduce fear of cancer coming back (recurrence) and anxiety in patients with renal cell carcinoma that is restricted to the site of origin, without evidence…
- Trial name
- NCT04688333
- Testing
- Internet-Based Intervention - Complete iConquerFear program, Quality-of-Life Assessment, Questionnaire Administration
- Sponsor
- City of Hope Medical Center
Liver Cancer, Metastatic Cancer
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have…
- Trial name
- NCT00003714
- Testing
- Pyrazoloacridine
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer
Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer
This research trial studies the development of a blood test for detecting anti-insulin-like growth factor II mRNA binding protein 3 (anti-IMP3) antibody and micro ribonucleic acid (microRNA) in patients with renal cell carcinoma…
- Trial name
- NCT00806650
- Testing
- gene expression analysis, protein expression analysis, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma
Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma
This study will assess whether Stereotactic Body Radiation Therapy (SBRT) can provide comparable local control, with similar or improved toxicity rates compared to Radio Frequency Ablation (RFA) when treating small renal cell…
- Trial name
- NCT02138578
- Testing
- SBRT, RFA
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and decrease the need for surgery.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00045630
- Testing
- carboplatin, gemcitabine, paclitaxel
- Where
- 128 sites in United States
- Volunteers
- 77 people
- Sponsor
- SWOG Cancer Research Network